1. Home
  2. PRTA vs RIGL Comparison

PRTA vs RIGL Comparison

Compare PRTA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • RIGL
  • Stock Information
  • Founded
  • PRTA 2012
  • RIGL 1996
  • Country
  • PRTA Ireland
  • RIGL United States
  • Employees
  • PRTA N/A
  • RIGL N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRTA Health Care
  • RIGL Health Care
  • Exchange
  • PRTA Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • PRTA 472.1M
  • RIGL 335.5M
  • IPO Year
  • PRTA N/A
  • RIGL 2000
  • Fundamental
  • Price
  • PRTA $8.20
  • RIGL $38.85
  • Analyst Decision
  • PRTA Buy
  • RIGL Buy
  • Analyst Count
  • PRTA 10
  • RIGL 5
  • Target Price
  • PRTA $14.86
  • RIGL $38.20
  • AVG Volume (30 Days)
  • PRTA 1.2M
  • RIGL 995.6K
  • Earning Date
  • PRTA 08-04-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • PRTA N/A
  • RIGL N/A
  • EPS Growth
  • PRTA N/A
  • RIGL N/A
  • EPS
  • PRTA N/A
  • RIGL 5.43
  • Revenue
  • PRTA $10,341,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • PRTA N/A
  • RIGL $59.93
  • Revenue Next Year
  • PRTA $389.77
  • RIGL N/A
  • P/E Ratio
  • PRTA N/A
  • RIGL $7.15
  • Revenue Growth
  • PRTA N/A
  • RIGL 105.62
  • 52 Week Low
  • PRTA $4.32
  • RIGL $12.66
  • 52 Week High
  • PRTA $22.83
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 58.73
  • RIGL 68.57
  • Support Level
  • PRTA $8.05
  • RIGL $39.00
  • Resistance Level
  • PRTA $8.73
  • RIGL $42.08
  • Average True Range (ATR)
  • PRTA 0.38
  • RIGL 2.32
  • MACD
  • PRTA -0.05
  • RIGL -0.37
  • Stochastic Oscillator
  • PRTA 47.62
  • RIGL 53.26

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: